Opus Genetics
IRD
79 hedge funds and large institutions have $204M invested in Opus Genetics in 2026 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 16 increasing their positions, 15 reducing their positions, and 6 closing their positions.
367% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 6
265% more capital invested
Capital invested by funds: $55.9M → $204M (+$148M)
34% more funds holding
Funds holding: 59 → 79 (+20)
23.5% more ownership
Funds ownership: 40.33% → 63.83% (+23%)
7% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 15
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CP
Caligan Partners
New York
|
+$21M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$17M |
| 3 |
BCM
Boxer Capital Management
San Diego,
California
|
+$7.78M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$7.46M |
| 5 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$6.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$10.7M |
| 2 |
PA
Perceptive Advisors
New York
|
-$8.61M |
| 3 |
MBAM
Mink Brook Asset Management
West Palm Beach,
Florida
|
-$3.72M |
| 4 |
VC
Voss Capital
Houston,
Texas
|
-$888K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$824K |
IRD Hedge Fund Activity: Q1 2026 in Review
79 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in Opus Genetics (IRD) for Q1 2026, worth a combined $204M — up 265% from $55.9M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new IRD positions and 6 closed out — a net gain of 22 holders — while 16 added to existing stakes and 15 trimmed.
The largest buyer was Caligan Partners, opening a new position worth an estimated $21M. The largest seller was Nantahala Capital Management, cutting an estimated $10.7M.
- 79 institutional investors held Opus Genetics (IRD) as of Q1 2026, up from 59 in Q4 2025.
- Funds reported $204M of Opus Genetics stock for Q1 2026, up 265% quarter-over-quarter.
- 28 funds opened new Opus Genetics positions in Q1 2026 and 6 closed out, a net change of +22 holders.
- The largest Opus Genetics buyer in Q1 2026 was Caligan Partners, an estimated $21M added.
- The largest Opus Genetics seller in Q1 2026 was Nantahala Capital Management, an estimated $10.7M sold.
Based on aggregated 13F filings for Q1 2026.